A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on a critical issue in cancer care: routine clinical reads are more prone to overdiagnosing progressive disease when compared to RECIST 1.1 interpretations. This discrepancy holds significant implications, potentially leading to the premature discontinuation of effective treatments for cancer clinical trial participants and patients under standard care.
In this study, mint Lesion software was utilized for the criteria-based reads, determining overall response assessments according to RECIST 1.1 criteria, and generating structured reports for the clinical trial's principal investigator.
To learn more about the study's insights into the discrepant assessments and the suggested steps for mitigating this issue, click here.
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
Related Resources
Related Resources
AI-powered quantification of bone metastasis in prostate cancer
Prostate cancer is the second most common cancer among men, and there are now effective treatments for the disease. New therapies available on the…
Radiomics - the next era of possibilities in Precision Medicine
Traditionally medical image analysis has been done through visual interpretation of static images. In the past decade, with the advent of…
Radiologist’s AI-powered workflow
We all have been exposed to the riveting news of artificial intelligence tools taking over diagnostic imaging. Due to the rapid increase in global…